PharmaEngine, Inc.
1Q 2026 Investors' Conference
2026/05/07

Jackie Chang,
Investor Relations Senior Manager

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. **Pricing and product initiatives of competitors**
2. **Legislative and regulatory developments and economic conditions**
3. **Delay or inability in obtaining regulatory approvals or bringing products to market**
4. **Fluctuations in currency exchange rates and general financial market conditions**
5. **Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products**
6. **Increased government pricing pressures**
7. **Interruptions in production**
8. **Loss of or inability to obtain adequate protection for intellectual property rights**
9. **Litigation**
10. **Loss of key executives or other employees**
11. **Adverse publicity and news coverage**

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

AGENDA

1. 1Q26 Operational Highlights
2. 1Q26 Operational Overview
3. R&D Update and Operation Strategy
4. Q&A

1Q26 Operational Highlights: Sustainable Growth and Pipeline Advancement

COMMERCIAL

ONIVYDE®
Indication Expansion

1. Sales of 1L combination therapy of ONIVYDE® in various EU countries have been boosting revenue growth
2. Continue to advance ONIVYDE's 1L PDAC marketing and sales strategies in Taiwan, providing patients with more treatment options

PIPELINE

New Project R&D
Progress Accelerated

1. PEP07 Phase I clinical trials for hematologic/solid tumors progressing toward MTD finding completion and will continue with dose expansion and combo trials.
2. PEP08 Phase I clinical trial for solid tumors was approved in Australia and Taiwan, the first patient was dosed in October 2025, progress advancing.
3. Other projects continue to move forward.

OPERATION

Operation with
Sustainable Growth

1. Cash dividend payout for the 12th consecutive year; 2025 cash dividend: NT$2/share
2. Began incorporating 30% of green energy in electricity usage in 2026

1Q26 Operational Overview

Sales and Royalties Drive Long-Term Growth

NT$(000)

Item / Year	2019	2020	2021	2022	2023	2024	2025	1Q26 YoY (%)
Taiwan Sales	180,389	214,828	235,469	277,594	278,547	279,990	277,133	58,076 (-14%)
Royalties from Europe and Asia	133,651	271,584	419,366	376,789	426,652	543,286	627,762	134,379 (+12%)
Milestone/Sub-license Revenue	0	569,600	0	0	62,470	1,700,028	6,521	47,340
Total	314,040	1,056,012	654,835	654,383	767,669	2,523,304	911,416	239,795 (+28%)

Taiwan Sales belongs to PharmaEngine, Inc.
Tiered royalties (high single-low double digit) in Europe/Asia (excl. TW) from Servier/IPSEN

1Q26 Financial Results

NT$(000)	1Q26	1Q25	Amount Change	% Change
Operating revenue	239,795	187,382	52,413	28%
Operating costs	15,235	12,384	2,851	23%
Gross profit	224,560	174,998	49,562	28%
Sales expenses	6,625	7,329	(704)	(10%)
G&A expenses	23,586	23,406	180	1%
R&D expenses	64,452	55,474	8,978	16%
Total operating expenses	94,663	86,209	8,454	10%
Operating income	129,897	88,789	41,108	46%
Total non-operating income and expenses	40,824	39,092	1,732	4%
Income before income tax	170,721	127,881	42,840	33%
Income tax expense	33,506	25,578	7,928	31%
Profit for the period	137,215	102,303	34,912	34%
EPS (NT$)	0.96	0.71	0.25	35%

R&D Update & Operation Strategy

Combination Therapy: The Future of Cancer Treatment

Indication	Standard of Care	# of Patients (2022)
Brain Cancer	**GBM:** 1. Maximal surgical resection 2. Radiotherapy with concomitant and maintenance temozolomide	177,139
Leukemia	**AML:** 1. Induction chemo: “7+3” (cytarabine + anthracycline) 2. Targeted therapy if mutation present: FLT3 inhibitors or IDH1/2 inhibitors	227,206
Pancreatic Cancer	1. Gemcitabine + nab-paclitaxel 2. NALIRIFOX 3. FOLFIRINOX 4. TS1	232,537

Source: Globocan 2022

PEP07 Phase I Clinical Trial Plan

Mono Dose Escalation



Combo Study

PEP07 + Standard of Care

PEP07 + New Chemical Entity

Following MTD confirmation, advancing to expansion and combination trial phases.

PEP08 Phase I Clinical Trial Plan

Mono Dose Escalation



Backfill cohorts are planned in selected doses

Combo Study

PEP08 + Standard of Care

PEP08 + New Chemical Entity

Following MTD confirmation, advancing to expansion and combination trial phases.

Deal Values of DDR/Synthetic Lethality Drugs in 2020-2025

Target	Name	Licensor	Licensee	Date	Phase at Deal	Upfront	Total Deal Value	Territory
Eight DDR Targets	**N/A**	Artios	Merck	Dec. 2020	IND Candidates	US$30M	US$890M	Worldwide
Three DDR Targets	**N/A**	Artios	Novartis	Apr. 2021	Discovery	US$20M	US$1.3B	Worldwide
WEE1	**SPH6162**	Shanghai Pharmaceuticals	HUYABIO	Nov. 2021	Preclinical	Undisclosed	Undisclosed	Worldwide (exclude Greater China)
ATR	**RP-3500**	Repare Therapeutics	Roche	Jun. 2022	Preclinical	US$135M	US$1.2B	Worldwide
KIF18A	**Sovilnesib (AMG650)**	Amgen	Volastra Therapeutics	Mar. 2023	Phase I	Undisclosed	Undisclosed	Worldwide
PARP1	**HRS-1167**	Hengrui	Merck	Oct. 2023	Preclinical	€160M	€1.4B	Worldwide (exclude China)
CHK1	**SRA-737**	CRT Pioneer Fund	Private US biopharma	Jan. 2024	Phase II	US$0.5M	US$290M and 500,000 shares	Worldwide
KIF18A	**MEN2501**	InSilicon	Stemline Therapeutics	Jan. 2025	Preclinical	US$20M	US$550M	Worldwide
WRN	**VVD-214**	Roche	Vividion	Jun. 2025	Phase I	Undisclosed	Undisclosed	Worldwide
PKMYT1	**Lunresertib**	Repare Therapeutics	Debiopharm	Jul. 2025	Phase I	US$10M	US$267M	Worldwide

Total Deal Value Range: US$267M ~ US$1.5B

Deal Values of PRMT5/MAT2A Drugs in 2020-2026

Target	Name	Licensor	Licensee	Date	Phase at Deal	Upfront	Total Deal Value	Territory
MAT2A, Pol Theta and Werner Helicase	**IDE397**	Ideaya	GSK	Jun. 2020	Preclinical	US$100M US$20M stock US$50M exercise fee for MAT2A		50% US profit share and ex-US royalties
PRMT5	**MRTX1719**	Mirati	BMS	Oct. 2023	Phase 1	1. US$4.8B equity acquired 2. ~US$1B upon acceptance by FDA of NDA for MRTX1719 in NSCLC		
MAT2A	**SYH2039**	CSPC	BeiGene	Dec. 2024	Phase 1	US$150M	US$1.835B	Worldwide
PRMT5	**PH020**	Puhe BioPharma	Bayer	Mar 2025	Phase I	Undisclosed	Undisclosed	Worldwide
MAT2A	**GH31**	Genhouse Bio	Gilead	Feb. 2026	IND	US$80M	US$1.450B	Worldwide

Total Deal Value Range: US$80M ~ US$1.835B

PEP08: Potential Indications, Number of Patients, and Market Size

Global PRMT5 Inhibitor Market Size Forecast



Eligible MTAP-Deletion Patients of Selected Indications (2022)



Source: Research intelo, Globocan 2022

Company Outlook for 2026-2030

New Dosage Form → Transformation → **New Chemical Entity** → Pipeline Build-up → **Precision Oncology (DDR & Synthetic Lethality)**

ONIVYDE® (Commercial)

2021

PEP07 (Preclinical → Phase I)
PEP09 (Drug Discovery → Late Drug Discovery/Lead Optimization)

AI-driven Drug Discovery Projects:
PEP08 (Drug Discovery → Preclinical → Phase I)
PEP10 (Drug Discovery → Late Drug Discovery/Lead Optimization)

2022

2025

PEP07 (Expansion → Phase II/III)
PEP09 (Preclinical → IND-enabled study → Phase I)

AI-driven Drug Discovery Projects:
PEP08 (Expansion → Phase II/III)
PEP10 (Preclinical → IND-enabled study → Phase I)

PEPXX *(Candidate Nomination)*

2026

2028

2030

Expand DDR and synthetic lethality pipeline dimension & target global precision oncology burgeoning market

Growth Drivers: Stronger R&D, Expanded Licensing Partnerships

2026-2030

- **Global Licensing: Worldwide rights exclude Taiwan**
- **Regional Licensing: China and Japan**
- **Collaboration: Treatment combo, e.g. SoC, new regimen**

PharmaEngine: Turning Potential into Value

1. Disciplined cash flow and robust R&D resourcing to advance a diversified pipeline in parallel
2. Comprehensive in-house R&D capabilities from drug development, pre-clinical to clinical execution
3. R&D team possesses a strong track record in co-developing innovative drugs with leading international CDMO and CRO partners.
4. Project flexibility for mono and combo therapies with SoC and NCE aligns with global treatment trend
5. Precision oncology pipeline drawing global pharma interest
6. PEP07 and PEP08 may lead the next wave of deals in the booming DDR/synthetic lethality markets

THANK YOU

PharmaEngine, Inc.